Description
PD-184352 is an anticancer chemotherapeutic MEK1/2 and Raf inhibitor that is particularly effective against cancers harboring B-Raf or RAS mutations such as V600E. PD-184352 enhances p53 accumulation and caspase activation, increases levels of pro-apoptotic Bim protein, and decreasing levels of cyclin D1, inducing cell cycle arrest and apoptosis in several cancer cell lines. This compound also induces tumor regression in animal models carrying lung tumors.